We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.
- Authors
Sargent, Daniel J; Marsoni, Silvia; Monges, Genevieve; Thibodeau, Stephen N; Labianca, Roberto; Hamilton, Stanley R; French, Amy J; Kabat, Brian; Foster, Nathan R; Torri, Valter; Ribic, Christine; Grothey, Axel; Moore, Malcolm; Zaniboni, Alberto; Seitz, Jean-Francois; Sinicrope, Frank; Gallinger, Steven
- Abstract
Prior reports have indicated that patients with colon cancer who demonstrate high-level microsatellite instability (MSI-H) or defective DNA mismatch repair (dMMR) have improved survival and receive no benefit from fluorouracil (FU) -based adjuvant therapy compared with patients who have microsatellite-stable or proficient mismatch repair (pMMR) tumors. We examined MMR status as a predictor of adjuvant therapy benefit in patients with stages II and III colon cancer.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Vol 28, Issue 20, p3219
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2009.27.1825